Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Prateek has more than 23 years of rich experience in Human Resource
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
Subscribe To Our Newsletter & Stay Updated
